How Roche helps protect women from cervical cancer
Be conclusive with CINtec® Histology
The CINtec® Histology test from Roche Tissue Diagnostics is FDA cleared. The test uses the advanced p16 biomarker to enhance identification of occult cervical lesions that may be missed by H&E or morphologic interpretation alone.
cobas® HPV Test
Screen with the cobas® HPV Test, the only clinically validated, FDA-approved and CE-IVD marked test for first line primary screening that simultaneously provides pooled results on known high-risk genotypes, and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one test.
CINtec® PLUS Cytology
Manage with CINtec® PLUS Cytology*, the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infection.
*CINtec® PLUS Cytology is a CE/IVD product, approved for clinical use. CINtec® PLUS Cytology is not available for this use in the United States. Check with your local Roche representative for the availability of products in your region and the applicable intended use.
Diagnose with CINtec® Histology – Enhances identification of occult lesions that may be missed by H&E or morphologic interpretation alone. The CINtec® Histology test is used for diagnostic confirmation of the presence or absence of high-grade cervical disease in tissue biopsy. The Roche p16INK4a clone is the only clinically validated biomarker of HPV-mediated transforming disease.